This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ESLOY or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
How Much Upside is Left in LeMaitre (LMAT)? Wall Street Analysts Think 25.24%
by Zacks Equity Research
The consensus price target hints at a 25.2% upside potential for LeMaitre (LMAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PETQ or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. LMAT: Which Stock Is the Better Value Option?
Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why
by Zacks Equity Research
Prestige Consumer (PBH) benefits from a robust healthcare brand portfolio and solid demand.
Here's Why Investors Should Retain Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.
Encompass Health (EHC) Up 41% in a Year: More Room for Growth?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
Here's Why Investors Should Hold Humana (HUM) in Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.
Cigna (CI) Eases Care Delivery With Prior Authorization Removal
by Zacks Equity Research
Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ABT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABT vs. LMAT: Which Stock Is the Better Value Option?
Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for May 23rd
by Zacks Equity Research
ONON, PKOH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 23, 2023.
What Makes LeMaitre Vascular (LMAT) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 8% and 7.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZBH or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VREX vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. LMAT: Which Stock Is the Better Value Option?
ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?